Friday, January 22, 2016 4:19:37 PM
Necuparanib Inhibits Pancreatic Cancer Progression and Invasion in a 3D Tumor and Stromal Cell Co-Culture System, AACR 2016
Presented at the AACR Special Conference on The
Function of Tumor Microenvironment in Cancer Progression
January 7 –10, 2016
San Diego, California, USA
The ability to inhibit proliferation in both tumor and stromal cells and enhance the therapeutic effect of gemcitabine demonstrates that necuparanib is a promising multitargeting agent for difficult-to-treat cancers such as desmoplastic pancreatic tumors. These findings support the current Phase 1/2 safety and efficacy study being performed in patients with metastatic pancreatic cancer.
http://www.momentapharma.com/docs/AACR-2016-January-poster-6x4-WEB.pdf
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM